ALK-positive large B-cell lymphoma
MONDO:0018225Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma is a very rare variant of diffuse large B-cell lymphoma (DLBCL) mainly affecting middle-aged immunocompetent men and characterized by a consistent primary involvement of lymph nodes (mainly in the cervical and mediastinum lymph nodes) and with infrequent extra nodal involvement of the bone marrow and other extra-nodal sites (head and neck region, liver, spleen, and gastrointestinal tract). It has an aggressive disease course, and is associated with a poor prognosis.
Also known as: ALK+ LBCL, ALK+ large B-cell lymphoma, ALK-DLBCL, ALK-positive large B-cell lymphoma, diffuse large B-cell lymphoma with expression of full-length ALK, diffuse large B-cell lymphoma with expression of full-length anaplastic lymphoma kinase
2003 clinical trials for this condition and its sub-types, 5 tagged with ALK-positive large B-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New cocktail aims to knock out tough lymphoma
Disease control OngoingThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Phase 1 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immunotherapy duo takes on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC